Endpoint Ventures

Indee Labs is focused on developing innovative hardware for gene delivery, specifically designed to facilitate the efficient development and scalable manufacture of gene-modified cell therapies, such as chimeric antigen receptor T cells. The company has created a non-viral intracellular delivery system that integrates with standard reagents, optimizing the recovery of viable modified cells with minimal disruption. Utilizing microfluidic vortex shedding technology, Indee Labs' system enables the gentle delivery of macromolecules, nucleic acids, and gene-editing complexes to various cell types. The company collaborates with the Australian National Fabrication Facility for its technology development and has established lab space at Bonneville Labs in Berkeley while expanding its operations with a new office in Sydney. Indee Labs has been associated with various prestigious incubators and programs, including NSW Health, IndieBio, Y Combinator, and MBC Biolabs.

Shasqi, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2018. The company specializes in the development of its proprietary CAPAC (Click Activated Protodrugs Against Cancer) platform, which utilizes click chemistry for localized drug activation in oncology. This innovative approach allows for the activation of prodrugs directly at tumor sites by employing a polymer gel that concentrates the drug, minimizing systemic exposure and associated toxicity. Shasqi’s technology enables a powerful localized therapy when a click chemistry reagent is localized in the tumor area, activating the protodrug infused systemically. The efficacy of this platform has already been demonstrated in human applications, paving the way for future advancements in click-chemistry-based cancer therapies.

Viosera Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies to combat antibiotic resistance, particularly targeting methicillin-resistant Staphylococcus aureus (MRSA). Founded in July 2016, the company is headquartered in Sunnyvale, California, with additional operations in St. Louis, Missouri. Viosera's flagship product, VT1, is designed to treat MRSA bloodstream infections. The company employs artificial intelligence to identify and develop drug combinations that predict and block resistance evolution in both bacterial infections and cancer treatment. Through these advancements, Viosera aims to provide effective solutions that address the growing threat of antibiotic resistance, ultimately improving patient outcomes.

FidoCure is dedicated to advancing cancer care for dogs through AI-driven precision medicine. The company utilizes data from naturally occurring canine cancers, combining next-generation sequencing with clinical insights to create the largest proprietary learning database for canine oncology. FidoCure offers personalized medicine services that go beyond traditional chemotherapy and radiation, collecting tissue samples for DNA sequencing to identify genetic mutations impacting treatment. This approach allows for the development of targeted therapies aimed at effectively attacking cancer cells. By bridging the gap between human and veterinary oncology, FidoCure enhances comparative oncology, improving treatment outcomes for both pets and humans while addressing a significant unmet need in canine cancer care.

Synkrino Biotherapeutics is a biotechnology company focused on discovering and developing innovative drug targets derived from the immune systems of patients. The company is dedicated to creating novel therapeutics aimed at treating diseases driven by immune responses and inflammation. Utilizing its AI Immunology Discovery Engine, Synkrino employs neural networks and machine learning to analyze immune tissue, allowing for the repeatable identification of biologically-valid drug targets. This approach not only enhances the potential for effective treatments but also aims to improve patient outcomes. Additionally, Synkrino is working on a rapid, portable field test for the RNA virus responsible for COVID-19, adapting its analytical methods for public health screening in pediatric rheumatology and other critical health areas.

Meru Health, Inc. is a digital healthcare company based in San Mateo, California, with additional offices in Palo Alto, California, and Helsinki, Finland. Founded in 2015, it specializes in providing a mobile application that connects patients with licensed therapists through a structured 12-week program aimed at addressing mental health issues such as stress, depression, anxiety, and burnout. The platform combines continuous remote clinician support with at-home lessons and practices, including cognitive behavioral therapy and coaching in sleep and nutrition. By offering cost-effective and clinically proven digital therapeutic solutions, Meru Health empowers individuals to improve their mental well-being while also aiming to reduce overall healthcare costs.

HelpWear Inc. is a Canadian company based in Toronto, founded in 2015, that focuses on enhancing at-home healthcare through innovative wearable technology. The company develops an affordable and accessible heart monitoring device designed to detect heart attacks and provide real-time alerts to emergency medical services. This waterproof device not only stores vital cardiovascular data but also features an embedded emergency contact system, ensuring that patients with heart ailments can receive timely assistance and maintain communication with healthcare providers regarding their health status. HelpWear's approach emphasizes clinical need-driven innovation, aiming to address both patient requirements and the demands of the healthcare system.

BillionToOne Inc. is a precision diagnostics company focused on developing advanced genetic testing platforms that detect and quantify diseases at the molecular level. Established in 2016 and headquartered in Menlo Park, California, the company offers a noninvasive prenatal screening solution called UNITY, which analyzes fetal cell-free DNA from a single blood sample provided by the mother. This test can identify single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and thalassemia, thereby providing a safer alternative to invasive procedures like amniocentesis. Beyond prenatal diagnostics, BillionToOne is also developing oncology assays that enable the detection of actionable mutations and monitor tumor burden through blood samples, allowing for more precise therapy selection and monitoring. The company's innovative technologies aim to make genetic testing both accurate and accessible, ensuring that a broader spectrum of patients can benefit from advanced medical diagnostics.

BillionToOne Inc. is a precision diagnostics company focused on developing advanced genetic testing platforms that detect and quantify diseases at the molecular level. Established in 2016 and headquartered in Menlo Park, California, the company offers a noninvasive prenatal screening solution called UNITY, which analyzes fetal cell-free DNA from a single blood sample provided by the mother. This test can identify single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and thalassemia, thereby providing a safer alternative to invasive procedures like amniocentesis. Beyond prenatal diagnostics, BillionToOne is also developing oncology assays that enable the detection of actionable mutations and monitor tumor burden through blood samples, allowing for more precise therapy selection and monitoring. The company's innovative technologies aim to make genetic testing both accurate and accessible, ensuring that a broader spectrum of patients can benefit from advanced medical diagnostics.